BioStem Technologies CEO to Present at Biotech Showcase 2025
BioStem Technologies (OTC: BSEM) has announced that CEO Jason Matuszewski will present a corporate overview at the Biotech Showcase 2025 conference in San Francisco. The presentation is scheduled for Monday, January 13, 2025, at 2:30 PM PT on Track Yosemite-C and will be available via webcast.
The conference, now in its 17th year, brings together biotechnology investors and pharmaceutical executives from around the world. BioStem's senior management will also be available for one-on-one meetings during the event, which runs from January 13-15, 2025.
BioStem Technologies specializes in developing and manufacturing placental-derived products for advanced wound care using their proprietary BioREtain® processing method. The company's portfolio includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®, all processed at their FDA registered and AATB accredited facility in Pompano Beach, Florida.
BioStem Technologies (OTC: BSEM) ha annunciato che il CEO Jason Matuszewski presenterà una panoramica aziendale alla conferenza Biotech Showcase 2025 che si terrà a San Francisco. La presentazione è programmata per lunedì 13 gennaio 2025, alle 14:30 PT nella Sala Yosemite-C e sarà disponibile tramite webcast.
La conferenza, che quest’anno festeggia il suo 17° anniversario, riunisce investitori nel settore biotecnologico e dirigenti delle aziende farmaceutiche di tutto il mondo. Anche la direzione senior di BioStem sarà disponibile per incontri individuali durante l’evento, che si svolgerà dal 13 al 15 gennaio 2025.
BioStem Technologies è specializzata nello sviluppo e nella produzione di prodotti a base di placenta per la cura avanzata delle ferite, utilizzando il loro metodo di elaborazione proprietario BioREtain®. Il portafoglio dell'azienda include AmnioWrap2™, VENDAJE®, VENDAJE AC® e VENDAJE OPTIC®, tutti elaborati presso la loro struttura registrata dalla FDA e accreditata dall'AATB a Pompano Beach, Florida.
BioStem Technologies (OTC: BSEM) ha anunciado que el CEO Jason Matuszewski presentará una visión corporativa en la conferencia Biotech Showcase 2025 en San Francisco. La presentación está programada para el lunes 13 de enero de 2025, a las 2:30 PM PT en la sala Yosemite-C y estará disponible a través de una transmisión en vivo.
La conferencia, que celebra su 17° año, reúne a inversores en biotecnología y ejecutivos farmacéuticos de todo el mundo. La alta dirección de BioStem también estará disponible para reuniones individuales durante el evento, que se llevará a cabo del 13 al 15 de enero de 2025.
BioStem Technologies se especializa en el desarrollo y fabricación de productos derivados de placenta para el cuidado avanzado de heridas utilizando su método de procesamiento patentado BioREtain®. La cartera de la empresa incluye AmnioWrap2™, VENDAJE®, VENDAJE AC® y VENDAJE OPTIC®, todos procesados en sus instalaciones registradas por la FDA y acreditadas por la AATB en Pompano Beach, Florida.
BioStem Technologies (OTC: BSEM)는 CEO Jason Matuszewski가 샌프란시스코에서 열리는 Biotech Showcase 2025 컨퍼런스에서 기업 개요를 발표할 것이라고 발표했습니다. 발표는 2025년 1월 13일 월요일, 오후 2:30 PT의 Yosemite-C 트랙에서 진행되며, 웹캐스트를 통해 시청할 수 있습니다.
이번 컨퍼런스는 17주년을 맞이하며, 전 세계의 생명공학 투자자와 제약 경영진이 모입니다. BioStem의 고위 경영진도 2025년 1월 13일부터 15일 사이에 열리는 행사 동안 1:1 미팅을 위해 참석할 예정입니다.
BioStem Technologies는 자사의 독점 BioREtain® 가공 방법을 사용하여 고급 상처 치료를 위한 태반 유래 제품의 개발 및 제조를 전문으로 하고 있습니다. 회사의 포트폴리오에는 플로리다 주 폼파노 비치에 있는 FDA 등록 및 AATB 인증 시설에서 가공된 AmnioWrap2™, VENDAJE®, VENDAJE AC® 및 VENDAJE OPTIC®가 포함되어 있습니다.
BioStem Technologies (OTC: BSEM) a annoncé que le PDG Jason Matuszewski présentera un aperçu de l'entreprise lors de la conférence Biotech Showcase 2025 à San Francisco. La présentation est prévue pour le lundi 13 janvier 2025, à 14h30 PT dans la salle Yosemite-C et sera disponible par webcast.
La conférence, qui célèbre sa 17e année, réunit des investisseurs en biotechnologie et des cadres pharmaceutiques du monde entier. La direction de BioStem sera également disponible pour des réunions individuelles pendant l'événement, qui se déroulera du 13 au 15 janvier 2025.
BioStem Technologies se spécialise dans le développement et la fabrication de produits dérivés du placenta pour les soins avancés des plaies en utilisant leur méthode de traitement propriétaire BioREtain®. Le portefeuille de l'entreprise comprend AmnioWrap2™, VENDAJE®, VENDAJE AC® et VENDAJE OPTIC®, tous transformés dans leurs installations enregistrées par la FDA et accréditées par l'AATB à Pompano Beach, en Floride.
BioStem Technologies (OTC: BSEM) hat bekannt gegeben, dass CEO Jason Matuszewski einen Unternehmensüberblick auf der Biotech Showcase 2025 Konferenz in San Francisco präsentieren wird. Die Präsentation ist für Montag, den 13. Januar 2025, um 14:30 Uhr PT im Track Yosemite-C geplant und wird über einen Webcast verfügbar sein.
Die Konferenz, die in ihr 17. Jahr geht, bringt Investoren aus der Biotechnologie und Führungskräfte der Pharmaindustrie aus der ganzen Welt zusammen. Auch das obere Management von BioStem wird während der Veranstaltung, die vom 13. bis 15. Januar 2025 stattfindet, für Einzelgespräche zur Verfügung stehen.
BioStem Technologies hat sich auf die Entwicklung und Herstellung von plazentabasierten Produkten für die moderne Wundversorgung spezialisiert und verwendet dabei ihre proprietäre BioREtain® Verarbeitungsmethode. Das Portfolio des Unternehmens umfasst AmnioWrap2™, VENDAJE®, VENDAJE AC® und VENDAJE OPTIC®, die alle in ihren von der FDA registrierten und von der AATB akkreditierten Einrichtungen in Pompano Beach, Florida, verarbeitet werden.
- None.
- None.
Presentation to be webcast at 2:30 PM PT on Monday, January 13, 2025
POMPANO BEACH, Fla., Jan. 02, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces that Jason Matuszewski, the Company’s Chief Executive Officer, will present a corporate overview and update at the Biotech Showcase 2025 conference, which is taking place in San Francisco, CA January 13-15, 2025. BioStem’s senior management will also host one-on-one meetings during the conference.
Biotech Showcase 2025 Presentation Details:
Date: Monday, January 13, 2025
Time: 2:30 PM PT
Track: Yosemite-C
Webcast Link: HERE
Webcast Archive: HERE
Request a Meeting with Management:
To schedule a one-on-one meeting at the Biotech Showcase conference or in San Francisco January 13-15, please email adamh@pcgadvisory.com.
About Biotech Showcase:
Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather at Biotech Showcase during this bellwether week which sets the tone for the coming year. Now in its 17th year, this well-established, highly respected conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings.
About BioStem Technologies, Inc. (OTC: BSEM):
BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain® processing method. BioREtain® has been developed by applying the latest research in advanced wound care, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB”). These systems and procedures are established per current Good Tissue Practices (“cGTP”) and current Good Manufacturing Processes (“cGMP”). Our portfolio of quality brands includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®. Each BioStem Technologies placental allograft is processed at the Company’s FDA registered and AATB accredited site in Pompano Beach, Florida.
For more information visit biostemtechnologies.com and follow us on Twitter and LinkedIn.
Join BioStem’s Distribution List & Social Media:
To follow the latest developments at BioStem, sign-up to the Company’s email distribution list HERE, and follow us on Twitter and LinkedIn.
Forward-Looking Statements:
Except for statements of historical fact, this release also contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements may be identified using words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements with respect to the operations of the Company, strategies, prospects and other aspects of the business of the Company are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. These factors include, but are not limited to: (1) the impact of any changes to the reimbursement levels for the Company’s products; (2) the Company faces significant and continuing competition, which could adversely affect its business, results of operations and financial condition; (3) rapid technological change could cause the Company’s products to become obsolete and if the Company does not enhance its product offerings through its research and development efforts, it may be unable to effectively compete; (4) to be commercially successful, the Company must convince physicians that its products are safe and effective alternatives to existing treatments and that its products should be used in their procedures; (5) the Company’s ability to raise funds to expand its business; (6) the Company has incurred significant losses since inception and may incur losses in the future; (7) changes in applicable laws or regulations; (8) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; (9) the Company’s ability to maintain production of its products in sufficient quantities to meet demand; and (10) the COVID-19 pandemic and its impact, if any, on the Company’s fiscal condition and results of operations; You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Although it may voluntarily do so from time to time, the Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.
BioStem Technologies, Inc.:
Phone: 954-380-8342
Website: http://www.biostemtechnologies.com
E-Mail: info@biostemtech.com
Twitter: @BSEM_Tech
Facebook: BioStemTechnologies
LinkedIn: BioStem Technologies LinkedIn
PCG Advisory
Jeff Ramson
jramson@pcgadvisory.com
646-863-6893
FAQ
When and where will BioStem Technologies (BSEM) present at Biotech Showcase 2025?
What products are in BioStem Technologies' (BSEM) current portfolio?
What is BioStem Technologies' (BSEM) proprietary processing method?
What accreditations does BioStem Technologies' (BSEM) manufacturing facility have?
How can investors schedule meetings with BSEM management during Biotech Showcase 2025?
